Drug intelligence / Profile preview

mAb57-26

Development stage: Preclinical
Lead developer: LeafBio
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

mAb57-26 is a monoclonal antibody developed by Mapp Biopharmaceutical and LeafBio for the treatment of pan-Ebolavirus infections, with a specific focus on Sudan virus disease (SVD). It functions as a virus-neutralizing antibody, targeting the viral glycoprotein to inhibit viral entry into host cells. Currently in the IND-enabling stage, mAb57-26 is designed for intravenous administration and aims to provide a therapeutic option for outbreaks caused by various Ebolavirus species, including the Sudan ebolavirus.

Targets

Zaire ebolavirus glycoprotein

Beyond the preview

Go deeper on mAb57-26.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mAb57-26.

Explore the full profile